135 Wood Street
United States - Map
NanoViricides, Inc. a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, a injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; and DengueCide, a treatment against Dengue viruses. It is also developing RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.
|Dr. Anil R. Diwan Ph.D.,
Chairman, Pres and Sec.
|Dr. Eugene Seymour M.D., MPH,
Chief Exec. Officer and Director
|Ms. Meeta R. Vyas SB, MBA,
Interim Chief Fin. Officer and Principal Accounting Officer
|Dr. Randall W. Barton Ph.D.,
Chief Scientific Officer and Chief Regulatory Officer
|Dr. Jayant Tatake Ph.D.,
VP of R&D
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|